Cellosaurus logo
expasy logo

Cellosaurus HAL-01 (CVCL_1242)

[Text version]
Cell line name HAL-01
Synonyms HAL-O1; HAL01; HAL-1; HALO1
Accession CVCL_1242
Resource Identification Initiative To cite this cell line use: HAL-01 (RRID:CVCL_1242)
Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: COSMIC cell lines project.
Population: Japanese.
Doubling time: 32 hours (PubMed=2027299); ~48 hours (DSMZ=ACC-610).
Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526; Sanger).
Omics: Deep exome analysis.
Omics: DNA methylation analysis.
Omics: Deep quantitative proteome analysis.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Omics: Transcriptome analysis by RNAseq.
Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
Sequence variations
  • Gene fusion; HGNC; 4977; HLF + HGNC; 11633; TCF3; Name(s)=TCF3-HLF, E2A-HLF; Note=In frame (PubMed=1516826).
  • Mutation; HGNC; 7978; NR3C1; Simple; p.Arg366Lysfs*8 (c.1096dup); Zygosity=Heterozygous (PubMed=35124168).
  • Mutation; HGNC; 7978; NR3C1; Simple; p.Arg477Gly (c.1429C>G) (p.Arg478Gly, c.1432C>G); Zygosity=Heterozygous (PubMed=35124168).
Genome ancestry Source: PubMed=30894373

Origin% genome
African0
Native American0.89
East Asian, North78.59
East Asian, South19.2
South Asian0
European, North0
European, South1.33
Disease B acute lymphoblastic leukemia with TCF3-HLF rearrangement (NCIt: C199241)
B-lymphoblastic leukemia/lymphoma with t(17;19) (ORDO: Orphanet_641375)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Sex of cell Female
Age at sampling 17Y
Category Cancer cell line
STR profile Source(s): Cosmic-CLP=949153; DSMZ=ACC-610; RCB=RCB0540

Markers:
AmelogeninX
CSF1PO11,12
D2S133818,24
D3S135815
D5S81812,13
D7S82010,12
D8S117913,15
D13S31711
D16S5399,11
D18S5113,14
D19S43312,14
D21S1129
FGA20,22
Penta D9,10
Penta E11,17
TH016,8
TPOX8,11
vWA16,17

Run an STR similarity search on this cell line
Publications

PubMed=2027299
Ohyashiki K., Fujieda H., Miyauchi J., Ohyashiki J.H., Tauchi T., Saito M., Nakazawa S., Abe K., Yamamoto K., Clark S.C., Toyama K.
Establishment of a novel heterotransplantable acute lymphoblastic leukemia cell line with a t(17;19) chromosomal translocation the growth of which is inhibited by interleukin-3.
Leukemia 5:322-331(1991)

PubMed=1516826; DOI=10.1101/gad.6.9.1608
Hunger S.P., Ohyashiki K., Toyama K., Cleary M.L.
Hlf, a novel hepatic bZIP protein, shows altered DNA-binding properties following fusion to E2A in t(17;19) acute lymphoblastic leukemia.
Genes Dev. 6:1608-1620(1992)

DOI=10.11418/jtca1981.15.4_211
Matsuo Y., Okochi A., Ariyasu T., Iimura E., Ohno T.
Identification of cell lines with variable numbers of tandem repeat (VNTR) amplified by polymerase chain reaction.
Tissue Cult. Res. Commun. 15:211-219(1996)

PubMed=9680106; DOI=10.1016/S0145-2126(98)00050-2
Matsuo Y., Drexler H.G.
Establishment and characterization of human B cell precursor-leukemia cell lines.
Leuk. Res. 22:567-579(1998)

PubMed=10739008; DOI=10.1016/S0145-2126(99)00182-4
Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.
Frequent microsatellite instability and BAX mutations in T cell acute lymphoblastic leukemia cell lines.
Leuk. Res. 24:255-262(2000)

DOI=10.1016/B978-0-12-221970-2.50457-5
Drexler H.G.
The leukemia-lymphoma cell line factsbook.
(In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001)

PubMed=11226526; DOI=10.1016/S0145-2126(00)00121-1
Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.
Corrigendum to: Frequent microsatellite instability and BAX mutations in T cell acute lymphoblastic leukemia cell lines Leukemia Research 24 (2000), 255-262.
Leuk. Res. 25:275-278(2001)

PubMed=14504097; DOI=10.1182/blood-2003-02-0418
Taketani T., Taki T., Sugita K., Furuichi Y., Ishii E., Hanada R., Tsuchida M., Sugita K., Ida K., Hayashi Y.
FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy.
Blood 103:1085-1088(2004)

PubMed=20147975; DOI=10.1038/leu.2010.8
Akahane K., Inukai T., Inaba T., Kurosawa H., Look A.T., Kiyokawa N., Fujimoto J., Goto H., Endo M., Zhang X., Hirose K., Kuroda I., Honna H., Kagami K., Goi K., Nakazawa S., Sugita K.
Specific induction of CD33 expression by E2A-HLF: the first evidence for aberrant myeloid antigen expression in ALL by a fusion transcription factor.
Leukemia 24:865-869(2010)

PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113
Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=20519628; DOI=10.1182/blood-2009-09-244673
Hirose K., Inukai T., Kikuchi J., Furukawa Y., Ikawa T., Kawamoto H., Oram S.H., Gottgens B., Kiyokawa N., Miyagawa Y., Okita H., Akahane K., Zhang X.-C., Kuroda I., Honna H., Kagami K., Goi K., Kurosawa H., Look A.T., Matsui H., Inaba T., Sugita K.
Aberrant induction of LMO2 by the E2A-HLF chimeric transcription factor and its implication in leukemogenesis of B-precursor ALL with t(17;19).
Blood 116:962-970(2010)

PubMed=20575032; DOI=10.1002/ajh.21738; PMCID=PMC7159455
Inukai T., Zhang X.-R., Kameyama T., Suzuki Y., Yoshikawa K., Kuroda I., Nemoto A., Akahane K., Sato H., Goi K., Nakamoto K., Hamada J.-i., Tada M., Moriuchi T., Sugita K.
A specific linkage between the incidence of TP53 mutations and type of chromosomal translocations in B-precursor acute lymphoblastic leukemia cell lines.
Am. J. Hematol. 85:535-537(2010)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=29786757; DOI=10.1007/s12185-018-2474-7
Tomoyasu C., Imamura T., Tomii T., Yano M., Asai D., Goto H., Shimada A., Sanada M., Iwamoto S., Takita J., Minegishi M., Inukai T., Sugita K., Hosoi H.
Copy number abnormality of acute lymphoblastic leukemia cell lines based on their genetic subtypes.
Int. J. Hematol. 108:312-318(2018)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=35124168; DOI=10.1016/j.jsbmb.2022.106068
Tamai M., Kasai S., Akahane K., Thu T.N., Kagami K., Komatsu C., Abe M., Watanabe A., Goi K., Miyake K., Inaba T., Takita J., Goto H., Minegishi M., Iwamoto S., Sugita K., Inukai T.
Glucocorticoid receptor gene mutations confer glucocorticoid resistance in B-cell precursor acute lymphoblastic leukemia.
J. Steroid Biochem. Mol. Biol. 218:106068.1-106068.12(2022)

PubMed=35354797; DOI=10.1038/s41467-022-29224-5; PMCID=PMC8967900
Leo I.R., Aswad L., Stahl M., Kunold E., Post F., Erkers T., Struyf N., Mermelekas G., Joshi R.N., Gracia-Villacampa E., Ostling P., Kallioniemi O.-P., Pokrovskaja Tamm K., Siavelis I., Lehtio J., Vesterlund M., Jafari R.
Integrative multi-omics and drug response profiling of childhood acute lymphoblastic leukemia cell lines.
Nat. Commun. 13:1691.1-1691.19(2022)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010; PMCID=PMC9387775
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)

Cross-references
Cell line collections (Providers) CLS; 305140
DSMZ; ACC-610
KCB; KCB 94011YJ
RCB; RCB0540
Cell line databases/resources CLO; CLO_0050976
cancercelllines; CVCL_1242
Cell_Model_Passport; SIDM00289
Cosmic-CLP; 949153
DepMap; ACH-002241
DSMZCellDive; ACC-610
LINCS_LDP; LCL-1046
Anatomy/cell type resources BTO; BTO:0004942
Biological sample resources BioSample; SAMN01821626
BioSample; SAMN03473501
Chemistry resources ChEMBL-Cells; CHEMBL3308233
ChEMBL-Targets; CHEMBL2366142
GDSC; 949153
PharmacoDB; HAL01_441_2019
PubChem_Cell_line; CVCL_1242
Encyclopedic resources Wikidata; Q54872387
Gene expression databases ArrayExpress; E-MTAB-783
ArrayExpress; E-MTAB-3610
GEO; GSM1669838
GEO; GSM5137716
Polymorphism and mutation databases Cosmic; 949153
Cosmic; 996300
Cosmic; 998738
Cosmic; 999742
Cosmic; 1037744
IARC_TP53; 27557
Proteomic databases PRIDE; PXD023662
PRIDE; PXD030304
Sequence databases EGA; EGAS00001000978
Entry history
Entry creation04-Apr-2012
Last entry update10-Sep-2024
Version number39